Stock Code 688278
中文 EN

About Us

Amoytop Biotech is an innovative biopharmaceutical company in China, specialized in R&D, manufacturing and marketing of regular and long-acting recombinant protein drugs. Focusing on the R&D of immune-related cytokine medicines, Amoytop Biotech is committed to providing better solutions for major diseases including viral hepatitis, malignant tumors and immunotherapy. In the future, Amoytop Biotech will specially focus on CHB (chronic hepatitis B) treatment to achieve breakthroughs in clinical cure.



Peginterferon Alfa-2b

Pegylated Recombinant Human Interferon alfa-2b

1st 40kD Y-shape branched PEG modified interferon alfa-2b injection



Recombinant Human Granulocyte Macrophage Colony-Stimulating Factor

National Medical Insurance, Category B ; Launched in 1997,The first China-made Molgramostim in marke



Recombinant Human Granulocyte Colony-Stimulating Factor

National Medical Insurance, Category B;Launched in 1999 and awarded as an excellent brand of biologi



Recombinant Human Interleukin 11

National Medical Insurance, Category B;Launched in 2005,,National standard bulk supplier of rHuIL-1


Research and Innovation

Committing to research and innovation of recombinant protein medicines, especially long-acting modification, Amoytop Biotech has established its own research teams and systems that composed of following modules: R&D center, medical development center, manufacturing center and quality center, covering all R&D aspects of innovative medicines from scientific discovery, laboratory trial, pilot trial, preclinical and clinical trial to industrialization. All modules are run and connected through Core Technology Platform and projectization, forming a complete closed loop for R&D cycle.


Xiamen Amoytop Biotech Co., Ltd.

  • Tel:86 592 6889105/108

    Email: /

    Add:No. 330 Wengjiao Road, Haicang, Xiamen, Fujian, China

  • Join Us:0592-7701210

  • Adverse Events Tel:86-592-6889111

    Adverse Events